<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pediatrics</journal-title>
</journal-title-group>
<issn pub-type="epub">2296-2360</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32181232</article-id>
<article-id pub-id-type="pmc">7059435</article-id>
<article-id pub-id-type="doi">10.3389/fped.2020.00064</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pediatrics</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A Pathogenic Missense Variant (c.1617G&gt;A, p.Met539Ile) in <italic>UBA1</italic> Causing Infantile X-Linked Spinal Muscular Atrophy (SMAX2)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xin Hua</given-names>
</name>
<xref ref-type="author-notes" rid="fn002">
<sup>†</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/558394/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Lin Mei</given-names>
</name>
<xref ref-type="author-notes" rid="fn002">
<sup>†</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/744664/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Xue</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Shui Zhen</given-names>
</name>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
</contrib>
</contrib-group>
<aff><institution>Children's Hospital of Fudan University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Chiara Fiorillo, University of Genoa, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Naveed Wasif, University Hospital Schleswig-Holstein, Germany; Muhammad Jawad Hassan, National University of Medical Sciences (NUMS), Pakistan</p>
</fn>
<corresp id="c001">*Correspondence: Shui Zhen Zhou <email>szzhou@shmu.edu.cn</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Genetic Disorders, a section of the journal Frontiers in Pediatrics</p>
</fn>
<fn fn-type="other" id="fn002">
<p>†These authors share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>8</volume>
<elocation-id>64</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>8</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Wang, Zhang, Yang and Zhou.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Wang, Zhang, Yang and Zhou</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p><bold>Background:</bold> Infantile X-linked spinal muscular atrophy (SMAX2) is a rare type of spinal muscular atrophy associated with <italic>UBA1</italic> variants.</p>
<p><bold>Methods:</bold> Clinical imaging and neurophysiological tests were performed on a Chinese patient with SMAX2. Further, focused panel sequencing of <italic>UBA1</italic> was carried out on samples of both the proband and his maternal relatives.</p>
<p><bold>Results:</bold> The proband, a 4-year-old boy with the SMAX2 phenotype, suffered from reduced exercise capacity since infancy. His other symptoms included speech difficulties, severe nasal tone, reduced distal muscle strength, areflexia, and inadequate sucking ability. The brain MRI of the proband's showed normal results but the electromyography results showed multiple peripheral neurogenic lesions. Five male members of the proband's family were affected with the SMAX2 phenotype. They presented similar symptoms and had experienced a long and autonomous life. Molecular analysis revealed a novel missense variant (c.1617G&gt;A, p.Met539Ile) in the exon 15 of <italic>UBA1</italic>. The proband's mother, as well as grandmother, carried the heterozygous missense <italic>UBA1</italic> variant; whereas, the male patients from the family carried the hemizygotic variant.</p>
<p><bold>Conclusions:</bold> The affected members in this Chinese family showed unique features such as extended life span, no fractures, and cramps as compared with previously reported SMAX2 cases. The novel missense variant (c.1617G&gt;A (p.Met539Ile) in UBA1 highlights the critical role of this gene in causing SMAX2 phenotype.</p>
</abstract>
<kwd-group>
<kwd>infantile X-linked spinal muscular atrophy</kwd>
<kwd>SMAX2</kwd>
<kwd>gene variant</kwd>
<kwd>ubiquitin-like modifier activating enzyme 1</kwd>
<kwd>UBA1 gene</kwd>
</kwd-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="25"></ref-count>
<page-count count="7"></page-count>
<word-count count="3881"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Spinal muscular atrophy (SMA) is a group of neuromuscular disorders characterized by the degeneration of the spinal cord motor neurons and muscular atrophy, often leading to early death (<xref ref-type="bibr" rid="B1">1</xref>). The most common form of SMA results from motor neuron 1 (<italic>SMN1</italic>) variants in 5q13, which are inherited in an autosomal recessive manner (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Deficiency or lower levels of the SMN protein expression affects the functional motor neurons in the anterior horn of the spinal cord and causes muscular dystrophy (<xref ref-type="bibr" rid="B3">3</xref>).</p>
<p>X-linked SMA is rare and mainly contains two forms (<xref ref-type="bibr" rid="B4">4</xref>): X-linked spinal and bulbar muscular atrophy (SMAX1, Kennedy disease, OMIM <ext-link ext-link-type="Omim" xlink:href="313200">313200</ext-link>: Online Mendelian Inheritance in Man 313200) and X-linked infantile spinal muscular atrophy [XL-SMA or SMAX2 (MIM301830)]. SMAX1 is an adult-onset disorder resulting from increase in a polymorphic tandem CAG repeat in the coding regions of androgen receptor (AR) gene on Xq12 (<xref ref-type="bibr" rid="B5">5</xref>). SMAX2 is an infantile-onset disease, characterized by hypotonia, areflexia, multiple congenital contractures and infantile deaths, that affect only the males. SMAX2 patients live shorter lives, suffer from respiratory insufficiency due to short and cupped ribs, and present no cognitive damage (<xref ref-type="bibr" rid="B4">4</xref>). In addition to these clinical characteristics, degeneration of anterior horn cells and normal SMN1 molecular genetic testing are also typical of SMAX2 cases (<xref ref-type="bibr" rid="B6">6</xref>). The genetic analyses of SMAX2 families have identified the ubiquitin-like modifier activating enzyme 1 (UBA1, previously referred to as UBE1) gene located on Xp11.3-q11.2 causing SMAX2 (<xref ref-type="bibr" rid="B7">7</xref>). To date, the exon 15 of UBA1 encoding the active adenylation domain (AAD) carries the four SMAX2-causing variants, including three missense (c1617G&gt;T:p.Met539Ile; c1639A&gt;G:p.Ser547Gly; c1670A&gt;T:Glu557Val) and one synonymous variant (c.1731C&gt;T:p.Asn577Asn) (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>Here, we present five Chinese male SMAX2 patients with partial clinical diagnosis of SMAX2, as ascertained by genetic analysis. However, the clinical manifestations of this case were different from other reported SMAX2 patients. Additionally, gene sequencing of <italic>UBA1</italic> revealed a novel missense variant, c.1617G&gt;A (p.Met539Ile).</p>
</sec>
<sec id="s2" sec-type="materials and methods">
<title>Materials and Methods</title>
<sec>
<title>Enrollment of Patients and Clinical Analyses</title>
<p>The proband was a 4-year-old boy, from Jiangsu province, with movement disorder, whose family had approached the Department of Neurology, Children's Hospital, Fudan University, to seek medical attention, in April 2017. The age of symptom-onset, changes in the exercise capacity, and the family history of the proband were investigated, and a comprehensive neurological examination along with brain magnetic resonance imaging (MRI) and electromyography were performed. According to the genetic characteristics of the family history, information regarding the clinical phenotype of other family members with movement disorder, was collected by telephone inquiry. This study was conducted in compliance with all the applicable laws and informed consent requirements.</p>
</sec>
<sec>
<title>Genetic Studies</title>
<p>DNA was isolated from 2 ml of the patient's peripheral blood, using QIAamp DNA Mini Kit. A focused panel sequencing was achieved by Ion Personal Genome Machine (PGMTM) sequencing system and Ion 316TM Chip v2 (<xref ref-type="bibr" rid="B10">10</xref>). Using the analysis software provided by the Ion torrent PGMTM server, the sequencing results were analyzed, and the data volume, average sequencing depth, and reference sequence matching degree were obtained. Then, the results were further analyzed by NextGENe software, interpreted in reference to the thousand human gene database (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org">http://www.1000genomes.org</ext-link>) (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>) and compared with internal Chinese database which contains about 20,000 cases including samples of children with neuromuscular diseases, such as mental retardation, epilepsy, dyskinesia, autism, etc, and other systemic diseases as well as samples from some parents with normal phenotype in our molecular medical center, the internal database contains both panel sequencing data which includes UBA1 gene and whole exome sequencing data. Following that, the clinical significance of the detected variation was explained using the Single Nucleotide Polymorphism Database (dbSNP) and the Human Gene Mutation Database (HGMD) (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). Also, in order to predict the possible effects of the variants on the protein, the PolyPhen-2, Sorting Intolerant from Tolerant (SIFT) and Mutation-Taster (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>) were applied in this study. Additionally, Sanger sequencing of <italic>UBA1</italic> was performed on peripheral blood DNA samples derived from the proband and his maternal relatives, to verify the variant. Mutation surveyor (Soft Genetics, State College, PA) was used to process the sequences against known wild-type control sequences (<xref ref-type="bibr" rid="B17">17</xref>).</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec>
<title>Clinical Phenotypes</title>
<p>The main complaint was the slow development of exercise capacity in the proband, since infancy, as compared to his peers. However, this phenomenon was not progressively aggravated. The proband learned to walk independently when he was 18 months old, but the running, climbing, jumping, and coordination abilities were worse than those of his peers. The proband also presented lisp and inadequate sucking ability (for example, in case of eating noodles). Physical examination showed high vaulted arch, difficulty in standing after squatting, normal muscle tension in the limbs, normal proximal muscle strength, distal limb muscle strength slightly weaker than level V, no knee reflex, thumb adduction, and flat the nar (<xref ref-type="fig" rid="F1">Figure 1</xref>). The proband's perceptual development was comparable to that of his peers.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>The clinical symptoms of the proband (a 4-year-old boy). Left picture shows that the boy has vaulted arch. Right picture shows that he has flat the nar in both hands.</p>
</caption>
<graphic xlink:href="fped-08-00064-g0001"></graphic>
</fig>
<p>The brain MRI investigations did not reveal any defects of the proband. Electromyography showed multiple peripheral neurogenic lesions (peripheral motor damage with mild demyelination, especially in lower limbs). The amplitude of compound muscle action potential (CMAP) in most of the examined motor nerves, reduced with or without a slight slowing of nerve conduction velocity (NCV). The F wave with the shortest latency from the right ulnar nerve and the bilateral sacral motor nerve were measured. In case of light contractions, the morphology of motor unit potential (MUP) in examined muscle parts was broad and the recruitment of heavy contractions was reduced or slightly reduced.</p>
</sec>
<sec>
<title>Phenotype of Family Members</title>
<p>We have studied an extended pedigree containing five affected male members, showing SMAX2 phenotypes (<xref ref-type="fig" rid="F2">Figure 2</xref>). These five male patients (individuals I:2, II:1, II:3, II:5, and IV:4) presented symptoms of reduced exercise capacity since infancy, normal cognition, speech difficulties, severe nasal tone and poor sucking ability. The phenomenon was not progressively aggravated, and they had the ability to live on their own as adults. Individual I:2 was still living at the age of 86. The symptoms at the onset of disease in II:1, II:3, and II:5 were similar to those of the proband and the athletic abilities of II:1, II:3, and II:5 were closer to those of a healthy person, mainly showing symptoms of speech difficulties and poor sucking ability.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Pedigree of SMAX2 family. Affected males are indicated by black squares and circles are females. Crossed symbols are deceased members. The proband is indicated by the arrow.</p>
</caption>
<graphic xlink:href="fped-08-00064-g0002"></graphic>
</fig>
</sec>
<sec>
<title>Genetic Analysis</title>
<p>A focused panel sequencing of the proband's DNA showed a sequence missense variant in exon 15 of the <italic>UBA1</italic> (<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NM_003334">NM_003334</ext-link> in GenBank): c.1617G&gt;A(p.Met539Ile). Sanger sequencing was carried out to verify the missense variant, which was predicted to be benign or tolerable, by Polyphen-2 (score:0.019) or SIFT (score:0.317), but pathogenic, by Mutation Taster (score:1.0). The variant c.1617G&gt;A(p.Met539Ile) has not been included in either the HGMD or the 1000G Project. This candidate is the only record in the internal database of our molecular medical center.</p>
<p><xref ref-type="fig" rid="F3">Figure 3</xref> shows the missense G-to-A substitution. As shown in <xref ref-type="fig" rid="F2">Figure 2</xref>, the proband's mother (III:14) and grandmother (II1:6) carried the heterozygous missense <italic>UBA1</italic> variant, while, the male patients (I:2 and II:5) carried the hemizygotic variant.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p><italic>UBA1</italic> sequence data. <bold>(A)</bold> Shows the pathogenic missense variant (c.1617G&gt;A) in proband's DNA sequence as compared with the reference DNA sequence. <bold>(B)</bold> Shows the heterozygous DNA sequence in the carrier mother. The red box shows the variant site.</p>
</caption>
<graphic xlink:href="fped-08-00064-g0003"></graphic>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>SMAX2 is a severe variant of infantile SMA, inherited in an X-linked manner. The clinical manifestations of SMAX2 are similar to the typical SMA symptoms caused by <italic>SMN1</italic> variants, such as hypotonia, tendon areflexia, and severe myasthenia (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B18">18</xref>). However, SMAX2 is characterized by facial dysmorphia, cryptorchidism, severe congenital contracture, and fractures. Most patients die of respiratory failure several months after birth (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B19">19</xref>). Baumbach et al. recommended that the diagnosis of SMAX2 should be based on clinical performances, with congenital hypotonia and areflexia on physical examination, congenital contractures and/or fractures, contractures at birth, and the loss of anterior horn cells in the spinal cord and brain stem, normal <italic>SMN1</italic> molecular sequencing, and male gender in a simple case or an X-linked manner of inheritance in families with multiple patients (<xref ref-type="bibr" rid="B18">18</xref>). Females who carry the heterozygous missense have a 50% chance of passing it on to the next generation and males who carry the hemizygotic variant are affected (<xref ref-type="bibr" rid="B18">18</xref>).</p>
<p>The incidence of SMAX2 is currently unknown. According to the National Center for Biotechnology Information (NCBI), the clinical and molecular studies of few SMAX2 families are reported so far (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). In <xref ref-type="table" rid="T1">Table 1</xref>, the clinical features and variant sites are reviewed in detail. All reported cases in the literature suffered a severe muscle weakness after birth and experienced a short lifespan. Among them, one patient reached the age of 13 years and the others died either within a few months or within 2 years after birth. Here, we presented the clinical symptoms and family history of SMAX2 in a Chinese family with a novel variant in the <italic>UBA1</italic>. Genetic analysis revealed a novel hemizygous missense variant (c.1617G&gt;A, p.Met539Ile) in <italic>UBA1</italic> in the proband and other patients as the key factor in the diagnosis of SMAX2. Although our patients showed the typical symptoms of SMAX2 such as areflexia, neurogenic damage, and muscle weakness, their clinical manifestations were significantly different from other cases, with late-onset disease, no progressive aggravation, high-vaulted palate arch, dysarthria, inadequate sucking ability, and a long lifespan.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Clinical symptoms and gene variant sites of SMAX2 patients reported in literature.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Patient</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Described by</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Hypotonia</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Areflexia</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Weakness</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Contractures</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Dysmorphic features</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Inarticulate</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Weak suck</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Respiratory distress</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Intelligence</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Death</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>EMG</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Musle biopsy</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>UBA1 variant</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Greenberg et al. (<xref ref-type="bibr" rid="B20">20</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Profound</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">Severe proximal</td>
<td align="left" colspan="1" rowspan="1" valign="top">All four extremities</td>
<td align="left" colspan="1" rowspan="1" valign="top">Myopathic face</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">18mo</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurogenic atrophy with some fiber hypertrophy</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1731C&gt;T<break></break>p.Asn577Asn</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Greenberg et al. (<xref ref-type="bibr" rid="B20">20</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Severe</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">Severe predominantly proximal</td>
<td align="left" colspan="1" rowspan="1" valign="top">Digital</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal</td>
<td align="left" colspan="1" rowspan="1" valign="top">Alive at age 13 years [Kobayashi et al. (<xref ref-type="bibr" rid="B11">11</xref>)]</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurogenic atrophy with some fiber hypertrophy</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1731C&gt;T <break></break>p.Asn577Asn</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">3</td>
<td align="left" colspan="1" rowspan="1" valign="top">Greenberg et al. (<xref ref-type="bibr" rid="B20">20</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Marked</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fingers, elbows, ankles, knees, hips</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">5mo</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurogenic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurogenic atrophy</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1731C&gt;T <break></break>p.Asn577Asn</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">4</td>
<td align="left" colspan="1" rowspan="1" valign="top">Greenberg et al. (<xref ref-type="bibr" rid="B20">20</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Severe</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fingers, elbows, knees, hips</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild potter-like face</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mechanical ventilation</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">11mo</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurogenic atrophy with some fiber hypertrophy</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1731C&gt;T <break></break>p.Asn577Asn</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dlamini et al. (<xref ref-type="bibr" rid="B4">4</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Marked</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">Global with movement distally in upper limbs, kyphoscoliosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fingers, elbows, ankles, knees, hips</td>
<td align="left" colspan="1" rowspan="1" valign="top">Myopathic face</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">From birth</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">4mo</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurogenic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurogenic atrophy with some fiber hypertrophy, perivascular inflammation</td>
<td align="left" colspan="1" rowspan="1" valign="top">c. 1670A&gt;Tp.Glu557Val</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Jedrzejowska (<xref ref-type="bibr" rid="B19">19</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Marked</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">Severe, lack of the movements of the lower limbs, persisted in proximal muscles of upper limbs</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fingers, wrists, elbows, shoulders, ankles, knees, hips</td>
<td align="left" colspan="1" rowspan="1" valign="top">Myopathic face, tent-shaped open mouth</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">In the second month of life</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal</td>
<td align="left" colspan="1" rowspan="1" valign="top">5.5mo</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1731C&gt;T <break></break>p.Asn577Asn</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">7</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ramser et al. (<xref ref-type="bibr" rid="B9">9</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1617 G&gt;T p.Met539Ile</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ramser et al. (<xref ref-type="bibr" rid="B9">9</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">NR</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1639 A&gt;G p.Ser547Gly</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">9(I 2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Our patient</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal proximal, mild weak distal</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">High-vaulted palate arch</td>
<td align="left" colspan="1" rowspan="1" valign="top">mild</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal</td>
<td align="left" colspan="1" rowspan="1" valign="top">Still alive at 86 years now</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1617G&gt;Ap.Met539Ile</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">10(II 1)</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">High-vaulted palate arch</td>
<td align="left" colspan="1" rowspan="1" valign="top">severe</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal</td>
<td align="left" colspan="1" rowspan="1" valign="top">Still alive at 68 years now</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">11(II 3)</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">High-vaulted palate arch</td>
<td align="left" colspan="1" rowspan="1" valign="top">severe</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal</td>
<td align="left" colspan="1" rowspan="1" valign="top">Still alive at 65 years now</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">12(II 5)</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">High-vaulted palate arch</td>
<td align="left" colspan="1" rowspan="1" valign="top">severe</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal</td>
<td align="left" colspan="1" rowspan="1" valign="top">Still alive at 60 years now</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1617G&gt;A p.Met539Ile</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">13(IV4)</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal proximal, mild weak distal</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">High-vaulted palate arch</td>
<td align="left" colspan="1" rowspan="1" valign="top">mild</td>
<td align="left" colspan="1" rowspan="1" valign="top">Y</td>
<td align="left" colspan="1" rowspan="1" valign="top">N</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal</td>
<td align="left" colspan="1" rowspan="1" valign="top">Alive at 5 years now</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurogenic</td>
<td align="left" colspan="1" rowspan="1" valign="top">NP</td>
<td align="left" colspan="1" rowspan="1" valign="top">c.1617G&gt;A p.Met539Ile</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>N, no; Y, yes; NP, not performed; NR, not reported</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p><italic>UBA1</italic> variants are the only known cause of SMAX2. The <italic>UBA1</italic> encoded protein participates in the ubiquitin conjugation to label the cells for protein degradation using the ubiquitin–proteasome system (UPS) (<xref ref-type="bibr" rid="B21">21</xref>). Damage to the UPS has been identified in several neurodegenerative diseases (<xref ref-type="bibr" rid="B22">22</xref>). <italic>UBA1</italic> variant may result in an abnormal and complex binding with gigaxonin, which plays an essential role in regulating axonal structure and neuronal maintenance (<xref ref-type="bibr" rid="B23">23</xref>). According to Ding et al. the amino-terminal BTB domain of gigaxonin binds to the <italic>UBA1</italic> and the carboxy-terminal kelch repeat domain directly links to the light chain of microtubule-associated protein 1B (MAP1B) (<xref ref-type="bibr" rid="B24">24</xref>). Over-expressed gigaxonin results in an increased MAP1B degradation, which further leads to neuron death, while reduction of MAP1B degradation enhances the survival rate of neurons (<xref ref-type="bibr" rid="B23">23</xref>). Briefly, <italic>UBA1</italic> missense variant leads to impaired degradation of MAP1B through abnormal gigaxonin, resulting in the death of anterior horn cells in the spinal cord and brain stem.</p>
<p>Only four variants of the <italic>UBA1</italic> have been reported so far, and all of them are localized in exon 15 (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). Balak et al. reported that synonymous C/T substitutions affect the methylation of exon 15 and thereby reduce the <italic>UBA1</italic> expression (<xref ref-type="bibr" rid="B7">7</xref>). In this study, we reported the novel base substitution c.1617G&gt;A (p.Met539Ile) in <italic>UBA1</italic> for the first time. Another missense variant c.1617G&gt;T, p.Met539Ile has been reported in another SMAX2 family (<xref ref-type="bibr" rid="B9">9</xref>). By comparing these two missense variants, we found that the two different base substitutions occurred at the same site and caused the same amino acid transition (Met is replaced by Ile). As we know, the C-terminus tail of ubiquitin should tightly bind the Adenosine triphosphate (ATP) in a narrow pocket in order to facilitate the acceptance of cysteine in the adjacent second catalytic cysteine half-domain (SCCH) (<xref ref-type="bibr" rid="B25">25</xref>). The latest research on the function of variants in <italic>UBA1</italic> suggests that the p.Met539Ile missense variants showed no statistically-reduced adenylation activity, leading to negligible changes in the relative enzymatic activity of UBA1 <italic>in vitro</italic> (<xref ref-type="bibr" rid="B7">7</xref>). This may explain why our patients exhibit different clinical performance and have a longer lifespan. The case reported in this study expanded the clinical and neuropathological spectrum related to the variants in the <italic>UBA1</italic> and suggested that an extended diagnosis ought to be considered in affected male infants.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>We have reported a novel missense variant c.1617G&gt;A (p. Met539Ile) in <italic>UBA1</italic> in a Chinese family with SMAX2. Our patients were distinguishable from previously reported cases, with unique features of late-onset disease, no progressive aggravation, vaulted palate arch, dysarthria, reduced sucking ability, and extended lifespan. This study expanded the spectrum of clinical and neuropathological findings associated with variants in <italic>UBA1</italic>.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.</p>
</sec>
<sec id="s7">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by Children's Hospital of Fudan University. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. Written informed consent was obtained from the minor(s)' legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>XW and LZ are the co-first authors. They participated in the study acquisition, analysis and interpretation of data, and drafted the manuscript. XY performed the analysis and interpretation of the clinical data. SZ conceived the idea for the study, designed and supervised the study, interpreted data, drafted and revised the manuscript content. All the authors have read and approved the final manuscript. They participated in the study acquisition, analysis and interpretation of data, and drafting of the manuscript.</p>
<sec>
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>We would like to thank the contribution of patient and his families. We would like to thank the Dr. Zhang Ping of the Molecular Medical Center for her help in responding to the reviewer's comments.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CH</given-names></name><name><surname>Lunn</surname><given-names>MR</given-names></name></person-group>. <article-title>Spinal muscular atrophy: advances in research and consensus on care of patients</article-title>. <source/>Curr Treat Options Neurol. (<year>2008</year>) <volume>10</volume>:<fpage>420</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s11940-008-0044-7</pub-id><pub-id pub-id-type="pmid">18990310</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burghes</surname><given-names>AH</given-names></name><name><surname>Beattie</surname><given-names>CE</given-names></name></person-group>. <article-title>Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?</article-title>
<source/>Nat Rev Neurosci. (<year>2009</year>) <volume>10</volume>:<fpage>597</fpage>–<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2670</pub-id><pub-id pub-id-type="pmid">19584893</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirth</surname><given-names>B</given-names></name></person-group>. <article-title>An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)</article-title>. <source/>Hum Mutat. (<year>2015</year>) <volume>15</volume>:<fpage>228</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1098-1004(200003)15:3&lt;228::AID-HUMU3&gt;3.0.CO;2-9</pub-id><pub-id pub-id-type="pmid">10679938</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dlamini</surname><given-names>N</given-names></name><name><surname>Josifova</surname><given-names>DJ</given-names></name><name><surname>Paine</surname><given-names>SM</given-names></name><name><surname>Wraige</surname><given-names>E</given-names></name><name><surname>Pitt</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>AJ</given-names></name><etal></etal></person-group>. <article-title>Clinical and neuropathological features of X-linked spinal muscular atrophy (SMAX2) associated with a novel mutation in the UBA1 gene</article-title>. <source/>Neuromuscul Disord. (<year>2013</year>) <volume>23</volume>:<fpage>391</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.nmd.2013.02.001</pub-id><pub-id pub-id-type="pmid">23518311</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Spada</surname><given-names>AR</given-names></name><name><surname>Wilson</surname><given-names>EM</given-names></name><name><surname>Lubahn</surname><given-names>DB</given-names></name><name><surname>Harding</surname><given-names>AE</given-names></name><name><surname>Fischbeck</surname><given-names>KH</given-names></name></person-group>. <article-title>Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy</article-title>. <source/>Nature. (<year>1991</year>) <volume>352</volume>:<fpage>77</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/352077a0</pub-id><pub-id pub-id-type="pmid">2062380</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahearn</surname><given-names>M</given-names></name><name><surname>Dressman</surname><given-names>D</given-names></name><name><surname>Yariz</surname><given-names>K</given-names></name><name><surname>Estrella</surname><given-names>E</given-names></name><name><surname>Basterrecha</surname><given-names>H</given-names></name><name><surname>Meindl</surname><given-names>A</given-names></name><etal></etal></person-group>
<source/>X-Linked Lethal Infantile (XL)-SMA: New Clinical Information, Variant Phenotypes, and Candidate Disease Gene Studies. Annual Clinical Meeting of the American-College-of-Medical-Genetics (<year>2004</year>).</mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balak</surname><given-names>CD</given-names></name><name><surname>Hunter</surname><given-names>JM</given-names></name><name><surname>Ahearn</surname><given-names>ME</given-names></name><name><surname>Wiley</surname><given-names>D</given-names></name><name><surname>D'urso</surname><given-names>G</given-names></name><name><surname>Baumbach-Reardon</surname><given-names>L</given-names></name></person-group>. <article-title>Functional characterizations of rare UBA1 variants in X-linked spinal muscular atrophy</article-title>. <source/>F1000Res. (<year>2017</year>) <volume>6</volume>:<fpage>1636</fpage>. <pub-id pub-id-type="doi">10.12688/f1000research.11878.1</pub-id><pub-id pub-id-type="pmid">29034082</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dressman</surname><given-names>D</given-names></name><name><surname>Ahearn</surname><given-names>ME</given-names></name><name><surname>Yariz</surname><given-names>KO</given-names></name><name><surname>Basterrecha</surname><given-names>H</given-names></name><name><surname>Martínez</surname><given-names>F</given-names></name><name><surname>Palau</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>X-linked infantile spinal muscular atrophy: clinical definition and molecular mapping</article-title>. <source/>Genet Med. (<year>2007</year>) <volume>9</volume>:<fpage>52</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1097/GIM.0b013e31802d8353</pub-id><pub-id pub-id-type="pmid">17224690</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramser</surname><given-names>J</given-names></name><name><surname>Ahearn</surname><given-names>ME</given-names></name><name><surname>Lenski</surname><given-names>C</given-names></name><name><surname>Yariz</surname><given-names>KO</given-names></name><name><surname>Hellebrand</surname><given-names>H</given-names></name><name><surname>von Rhein</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy</article-title>. <source/>Am J Hum Genet. (<year>2008</year>) <volume>82</volume>:<fpage>188</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2007.09.009</pub-id><pub-id pub-id-type="pmid">18179898</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loman</surname><given-names>NJ</given-names></name><name><surname>Constantinidou</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>JZ</given-names></name><name><surname>Halachev</surname><given-names>M</given-names></name><name><surname>Sergeant</surname><given-names>M</given-names></name><name><surname>Penn</surname><given-names>CW</given-names></name><etal></etal></person-group>. <article-title>High-throughput bacterial genome sequencing: an embarrassment of choice, a world of opportunity</article-title>. <source/>Nat Rev Microbiol. (<year>2012</year>) <volume>10</volume>:<fpage>599</fpage>–<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2850</pub-id><pub-id pub-id-type="pmid">22864262</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasmant</surname><given-names>E</given-names></name><name><surname>Parfait</surname><given-names>B</given-names></name><name><surname>Luscan</surname><given-names>A</given-names></name><name><surname>Goussard</surname><given-names>P</given-names></name><name><surname>Briand-Suleau</surname><given-names>A</given-names></name><name><surname>Laurendeau</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?</article-title>
<source/>Eur J Hum Gene. (<year>2015</year>) <volume>23</volume>:<fpage>596</fpage>–<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2014.145</pub-id><pub-id pub-id-type="pmid">25074460</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>L</given-names></name><name><surname>Zheng-Bradley</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Kulesha</surname><given-names>E</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Toneva</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>The 1000 Genomes Project: data management and community access</article-title>. <source/>Nat Methods. (<year>2012</year>) <volume>9</volume>:<fpage>459</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1974</pub-id><pub-id pub-id-type="pmid">22543379</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitts</surname><given-names>A</given-names></name><name><surname>Sherry</surname><given-names>S</given-names></name></person-group>
<source/>The Single Nucleotide Polymorphism Database (dbSNP) of Nucleotide Sequence Variation. National Center for Biotechnology Information (<year>2003</year>).</mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenson</surname><given-names>PD</given-names></name><name><surname>Ball</surname><given-names>EV</given-names></name><name><surname>Mort</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>AD</given-names></name><name><surname>Shiel</surname><given-names>JA</given-names></name><name><surname>Thomas</surname><given-names>NS</given-names></name><etal></etal></person-group>. <article-title>Human gene mutation database (HGMD): 2003 update</article-title>. <source/>Hum Mutat. (<year>2003</year>) <volume>21</volume>:<fpage>577</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1002/humu.10212</pub-id><pub-id pub-id-type="pmid">12754702</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adzhubei</surname><given-names>IA</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Peshkin</surname><given-names>L</given-names></name><name><surname>Ramensky</surname><given-names>VE</given-names></name><name><surname>Gerasimova</surname><given-names>A</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>A method and server for predicting damaging missense mutations</article-title>. <source/>Nat Methods. (<year>2010</year>) <volume>7</volume>:<fpage>248</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth0410-248</pub-id><pub-id pub-id-type="pmid">20354512</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>JM</given-names></name><name><surname>Rödelsperger</surname><given-names>C</given-names></name><name><surname>Schuelke</surname><given-names>M</given-names></name><name><surname>Seelow</surname><given-names>D</given-names></name></person-group>. <article-title>MutationTaster evaluates disease-causing potential of sequence alterations</article-title>. <source/>Nat Methods. (<year>2010</year>) <volume>7</volume>:<fpage>575</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth0810-575</pub-id><pub-id pub-id-type="pmid">20676075</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>K</given-names></name><name><surname>Sharp</surname><given-names>P</given-names></name></person-group>. <article-title>Simultaneous mutation detection of three homoeologous genes in wheat by high resolution melting analysis and Mutation Surveyor</article-title>. <source/>BMC Plant Biol. (<year>2009</year>) <volume>9</volume>:<fpage>143</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2229-9-143</pub-id><pub-id pub-id-type="pmid">19958559</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Baumbach-Reardon</surname><given-names>L</given-names></name><name><surname>Sacharow</surname><given-names>SJ</given-names></name><name><surname>Ahearn</surname><given-names>ME</given-names></name></person-group>
<article-title>Spinal muscular atrophy, x-linked infantile</article-title>. In: <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Bean</surname><given-names>LJH</given-names></name><name><surname>Stephens</surname><given-names>K</given-names></name><name><surname>Amemiya</surname><given-names>A</given-names></name></person-group>, editors. <source/>GeneReviews® [Internet].
<publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name> (<year>2008</year>). p. <fpage>1993</fpage>–<lpage>2019</lpage>.</mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jedrzejowska</surname><given-names>M</given-names></name><name><surname>Jakubowska-Pietkiewicz</surname><given-names>E</given-names></name><name><surname>Kostera-Pruszczyk</surname><given-names>A</given-names></name></person-group>. <article-title>X-linked spinal muscular atrophy (SMAX2) caused by <italic>de novo</italic> c.1731C&gt;T substitution in the UBA1 gene</article-title>. <source/>Neuromuscul Disord. (<year>2015</year>) <volume>25</volume>:<fpage>661</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.nmd.2015.05.001</pub-id><pub-id pub-id-type="pmid">26028276</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>F</given-names></name><name><surname>Fenolio</surname><given-names>KR</given-names></name><name><surname>Hejtmancik</surname><given-names>JF</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Willis</surname><given-names>JK</given-names></name><name><surname>Shapira</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>X-linked infantile spinal muscular atrophy</article-title>. <source/>Am J Dis Child. (<year>1988</year>) <volume>142</volume>:<fpage>217</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/archpedi.1988.02150020119045</pub-id><pub-id pub-id-type="pmid">3341327</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>HY</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Nie</surname><given-names>S</given-names></name><name><surname>Erdjument-Bromage</surname><given-names>H</given-names></name><name><surname>Tempst</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Regulation of cell cycle progression and gene expression by H2A deubiquitination</article-title>. <source/>Nature. (<year>2007</year>) <volume>449</volume>:<fpage>1068</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/nature06256</pub-id><pub-id pub-id-type="pmid">17914355</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedford</surname><given-names>L</given-names></name><name><surname>Paine</surname><given-names>S</given-names></name><name><surname>Rezvani</surname><given-names>N</given-names></name><name><surname>Mee</surname><given-names>M</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Mayer</surname><given-names>RJ</given-names></name></person-group>. <article-title>The UPS and autophagy in chronic neurodegenerative disease: six of one and half a dozen of the other–or not?</article-title>
<source/>Autophagy. (<year>2009</year>) <volume>5</volume>:<fpage>224</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.4161/auto.5.2.7389</pub-id><pub-id pub-id-type="pmid">19077533</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>E</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Pramanik</surname><given-names>S</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Yau</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival</article-title>. <source/>Nature. (<year>2005</year>) <volume>438</volume>:<fpage>224</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nature04256</pub-id><pub-id pub-id-type="pmid">16227972</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Kowal</surname><given-names>AS</given-names></name><name><surname>Nardine</surname><given-names>T</given-names></name><name><surname>Bhattacharya</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Microtubule-associated protein 1B: a neuronal binding partner for gigaxonin</article-title>. <source/>J Cell Biol. (<year>2002</year>) <volume>158</volume>:<fpage>427</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200202055</pub-id><pub-id pub-id-type="pmid">12147674</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>I</given-names></name><name><surname>Schindelin</surname><given-names>H</given-names></name></person-group>. <article-title>Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes</article-title>. <source/>Cell. (<year>2008</year>) <volume>134</volume>:<fpage>268</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.05.046</pub-id><pub-id pub-id-type="pmid">18662542</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>